Unknown PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT04868253

Efficacy and Safety of Combination EMB-001 as a Potential Smoking Cessation Treatment

Sponsor: Embera NeuroTherapeutics, Inc.

Conditions Smoking Cessation Tobacco Use Disorder

Interventions EMB-01

Updated 6 times since 2021 Last updated: May 26, 2021 Started: May 19, 2021 Primary completion: Dec 31, 2021 Completion: Dec 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Smoking Cessation and Tobacco Use Disorder and is currently ongoing. Embera NeuroTherapeutics, Inc. leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jun 2023 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3

Status: Recruiting → Unknown Status
Apr 2023 — Jun 2023 [monthly]

Recruiting PHASE2_PHASE3
Jun 2021 — Apr 2023 [monthly]

Recruiting PHASE2_PHASE3

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

May 2021 — Jun 2021 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Embera NeuroTherapeutics, Inc.
Foundation for a Smoke Free World INC
Rose Research Center, LLC

Data source: Rose Research Center, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Raleigh, United States